COVERSCAN [COVID-19]
Research type
Research Study
Full title
Mapping Organ Health in Recovery from COVID-19 Disease due to SARS-CoV-2 infection
IRAS ID
282636
Contact name
Mary Norris Xu
Contact email
Sponsor organisation
Perspectum Ltd
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Research Summary
To date, correctly, all of the Government’s efforts have been dedicated to providing sufficient hospital space, and the appropriate equipment, for treating the most serious cases of COVID-19. Equally, enormous resource is being dedicated to developing technologies that determine who has the disease, and who has developed antibodies to it. However, patients recovering from serious disease will also pose a huge, ongoing challenge. Not only are people with co-morbidities including underlying fatty liver disease, metabolic syndrome and diabetes at higher risk for complications with COVID-19; but patients discharged from hospital after severe COVID-19 are reported to have liver and kidney injuries, and impacts on pancreas and spleen. However, the extent of organ health/damage has not been mapped. \n\nThis is a prospective, longitudinal, observational cohort study looking at patients recovering from COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury. This proposed study aims to measure the prevalence of organ volume changes and damage in lungs, heart, kidney, liver, pancreas, spleen as assessed by MRI among those having recovered, or recovering, from the SARS-CoV-2 infection - participants will have a final MRI scan at 12 months. Assessing the severity and sequelae of COVID-19 in patients is crucial to enable global planning for health-care needs. The study includes up to 3 visits for MRI scans and blood tests over a 12 month period. All participants will receive standard-of-care by their healthcare provider/s.
Summary of Results
Key Messages from the COVERSCAN Study
The CoverScan study identified several key messages, of value to patients and researchers:
1. COVID-19 can have long-term effects on multiple organs: The study found evidence of organ damage in the heart, lungs, liver, and kidneys of patients who had recovered from COVID-19, even if they only experienced mild or moderate symptoms.
2. The risk of organ damage is higher in hospitalised patients: Patients who had been hospitalised with COVID-19 had a higher risk of organ damage compared to those who were not hospitalised.
3. Older age and pre-existing medical conditions are risk factors: The study found that older age and pre-existing medical conditions such as diabetes, hypertension, and obesity were risk factors for organ damage in patients with COVID-19. This information could help identify high-risk patients who may require closer monitoring and follow-up care.
4. Long-term monitoring is important: The study highlighted the importance of long-term monitoring of patients with long COVID-19, even in those with mild or moderate symptoms, to detect and manage any potential long-term complications.
Overall, the CoverScan multi-organ study highlights the importance of continued research and monitoring of patients with long COVID to better understand how the disease can have long-term effects on multiple organs.
CoverScan has been developed by Perspectum as a quantitative, semi-automated MRI method to measure multi-organ health, providing a UKCA and FDA 510(k) cleared tool. Piloted in diabetes and long COVID, CoverScan detects multi-organ effects more sensitively than biomarkers in routine care.Key Recent Academic Publications (as of 10-02-2023)
Roca-Fernandez, A., et al. (2023). Cardiac impairment in long COVID 1-year post-SARS-CoV-2 infection. Open Heart, 10, e002241. https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbcKmRTqgDd87GPSDH7K8-2FD6ilyyqSPtNKE0bWEheCmVUVSF9T1Ifhw0pz4wkhXEong-3D-3DHAm3_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLTdzJrsKHYOGRo3aBv7K9FjGh4DEhsvMl8C9nZZELb0Lf1cAkKktKKNfmXo-2FQEEw7Z4bGD8z14E82igMMUVMsVzAwU15gTlL48dJsYXhgCQpamUHHZpCgiP242-2FeH2MFX-2BHU694tvBqaexAICMJuBEoA-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=GoRpei5%2FCBsXKGM2FK%2Bb3LZaqOoSmQS8X8bU8vDrbCc%3D&reserved=0
Dennis, A., et al. (2023). Multi-organ impairment and Long COVID: a 1-year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine. Advance online publication. https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbUDusdECazRYlSZVNJulVTbhXt0UFVrjw-2FW-2FIx5EzI2aDXX2jQ-2B9RANJHNBGCNf7-2Bn-2FJfhoUCoCZEEv-2BqoNhucs-3DbO_C_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLTAEfsdUIeAfsMV3JHaGzGpisbcDzir3uMYxP4mAWaLUv-2FYXjW7Q2Hawb-2FDay1-2BUN07VLkOraegI5k9UfLv46USJRImeo54t8Z-2BfDADrskbocpsfRIuSF-2B9sfIjsFUVnLf4pZTqiqcqbf32gq15YKWrQ-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=KkUCqPsiUPEFKmSwef%2Fv1z7NirmrA7%2BzCFHcodV%2FrT8%3D&reserved=0
Borlotti, A., et al. (2022). The additive value of cardiovascular magnetic resonance in convalescent COVID-19 patients. Frontiers in Cardiovascular Medicine, 9, 854750. https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbebd-2Fr7k2hoipaRSxik15EYbzpqY5KMBmTGTr9Kt0-2B2qP8kXcGobJXKakqaexPHF4g-3D-3DCPPO_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLT6s8aoegluxldkJa6XW6xHtJuJWSemSmh4jNt5A038KUiNgitRj4LdkwzPyoaGEbGiGaxasVASYoyQWc45FJyr8pjRVeCDkJPKr7gs-2FqM5SYxuA6opkWpivVQwz7V4O5g1VAp-2F6iJ0un-2FmPh0XVImUA-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=HJg%2BFxVi3kTVncHnFJcILTj3M6yQjzqYsdWvhClkRV8%3D&reserved=0
Dennis, A., et al. (2021). Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open, 11(3), e048391. https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbYLcu6Wa5jZlZ-2Fw7JrIX24fRtFbUf0cUNq8vjSOvDR4zWReAu0EWvjrSrnf08-2Feh0A-3D-3DxCZ-_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLTBpkvg7VYwr3advHId-2FKfNSh1jSX7I-2Fb8ZU82kMRArLFWAPypcPaP7Z75n7ss8AhTXZqpd9X6a47rDPt7LxBz-2FvKwWrzJ14PS9fzhts0U-2BC-2Fyzonf8L-2BCAvdJZTSR1Uk6l1UyGgJlSrCrESpZTvk8Gg-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=4lPxdDWJTFeM7osLViykzlr9tJi9vFg6xI9xWliQZOc%3D&reserved=0
Live Webinars
During the study 16 live Q&A webinars were delivered summarising early study results and in response to the hundreds of email queries received each week by the study team from participants and the general public. Links to some of the webinars can be found here: https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbQMqAHTCPcH9OllbIJWmdl7gQ-2ByaVY6LwF3O5-2Bw1U4DJ3fILC9rjbxOxoAjXl5PSBmJO-2BOT9Jt8VqGmyTvBwgS8Kkb8B65XpXkQOHGxUD9c0Offk_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLTC4H4SU63fzwypielcxTOz8-2BQx7juYLYaxu-2BFrcY7Y9TuUwLFFB15Ec-2FCdBaAG8V3Lshi3e63fGuhi1PKlRDKaUTPBQSj1EbjVokf8GQPdC4h3SBwF396cmslh32u7IuM9dgkaMDZKpyrB3tfKyM2dA-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=PwybRbXACPt1lEoL1dQjjAv6wkwa8rAU49HfYTlHuLM%3D&reserved=0
Further Research
CoverScan is being utilised as part of the STIMULATE-ICP study – another U.K. study which aims to develop the best ways to care for people with long COVID. More details on STIMULATE-ICP can be found here: https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbcxQ4WI7UzyUj9TLRzEkOlEKMj67O3dM1ERckJ0P-2BRdk2EpV_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YIXIh4QpDjE7JyhfVn3slLTpnHdAr6qE-2Bg-2BomfyszaA6m13OPXE8kTK2cfTOUI-2FYE6BHdazy5lMM1aZ-2FiTPiJLoF-2Ff-2FkzHhwVtAtQ9tVA9TXC6gxNN5OVVGa4zI-2FqKlLQ-2Fqfjt0-2FgLfcyDhu5uK83LO7uIkoF8NWcCHy-2FfVePZVIQ-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C7d6709ddcf4e440a9ad008db253a3d1c%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638144704280391918%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=SwMWXlI0gehzEWtWL8SrjIOm6GcdiK4Q32x0J15ouls%3D&reserved=0
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
20/SC/0185
Date of REC Opinion
21 Apr 2020
REC opinion
Further Information Favourable Opinion